negative despite the use of standardized criteria to benefit. Discordance between HER2 IHC and FISH status, various by the discrepancy between local and central laboratories rft, May influence our interpretation of test results of lapatinib. For example, in the phase III trial of capecitabine with lapatinib or placebo, trial determines BTZ043 BTZ038 registering in patients with HER2-positive disease by IHC 3��ԧ֧